YL-15293, oral KRASG12C inhibitor
YL-15293 is a clinical-stage KRASG12C covalent inhibitor that potently and selectively inhibits the KRASG12C oncoprotein. A Phase 1 clinical trial exploring safety and efficacy in defined KRASG12C-mutated cancers is currently on hold.
Clinical Trials
NCT05173805, Phase 1 dose escalation in China, on hold